These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 18210890)
1. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib]. Zhang PL; Chen L Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890 [No Abstract] [Full Text] [Related]
2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626 [TBL] [Abstract][Full Text] [Related]
4. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674 [TBL] [Abstract][Full Text] [Related]
5. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib in the treatment of advanced non-small-cell lung cancer. Reck M Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595 [TBL] [Abstract][Full Text] [Related]
7. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612 [TBL] [Abstract][Full Text] [Related]
9. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Chiu CH; Tsai CM; Chen YM; Chiang SC; Liou JL; Perng RP Lung Cancer; 2005 Jan; 47(1):129-38. PubMed ID: 15603863 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361 [TBL] [Abstract][Full Text] [Related]
11. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. Garfield D J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972 [No Abstract] [Full Text] [Related]
12. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
13. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083 [TBL] [Abstract][Full Text] [Related]
14. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743 [TBL] [Abstract][Full Text] [Related]
15. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer]. Wang MZ; Zhong W; Zhang L; Li LY; Wang SL; Li JR; Zhang XT Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):221-4. PubMed ID: 18756941 [TBL] [Abstract][Full Text] [Related]
17. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811 [No Abstract] [Full Text] [Related]
18. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial]. Guan ZZ; Zhang L; Li LY; Jiang GL; Liu XY; Chu DT; Zhao HY; Li W Ai Zheng; 2005 Aug; 24(8):980-4. PubMed ID: 16086877 [TBL] [Abstract][Full Text] [Related]
19. Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Hotta K; Inoue A; Kiura K; Ueoka H; Nukiwa T; Tanimoto M Lung Cancer; 2005 Dec; 50(3):413-5. PubMed ID: 16154232 [No Abstract] [Full Text] [Related]
20. [Gefitinib in the treatment of refractory non-small cell lung cancer]. Xu JF; Zhou CC; Li AW Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):938-40. PubMed ID: 18478936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]